Athlos (Astra Zeneca)
External Link
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.
Wearables 2
Our research teams at the Lundquist Institute at Harbor-UCLA Medical Center and Caltech, are testing an experimental skin sensor to see if it can measure markers of lung infection without taking a blood sample. We are seeking your participation in our research to help develop this COPD flare-up early warning system.
Pulmonary Nodules
NIGHTINGALE Study
External Link
This is a randomized prospective observational study intended to show the clinical utility of the Percepta Nasal Swab in patients with a new lung nodule and a history of smoking. The test is designed to help to stratify the risk of primary lung cancer in both screening-identified and incidental nodules. The swab is a simple, office-based collection that involved a single, brief brushing of the nasal epithelium and employs RNA whole transcriptome sequencing. The test is run by a CLIA lab and is intended to help patients with benign nodules avoid unnecessary invasive procedures while optimizing the time to diagnosis and treatment for those with primary lung cancer.
Asthma
Asthma POCT
The Respiratory Research Center is looking for adults with asthma to participate in a research study with the goal to see if a new test can identify environmental allergies as well as the commonly used laboratory test.
IPF
MOONSCAPE Study
The study will evaluate the efficacy, safety, and pharmacokinetics of Vixarelimab in patients with IPF and in patients with SSc-ILD.
ELEVATE Study (PureTech)
ClinicalTrials.gov Identifier NCT05321420
A trial will evaluate the antifibrotic and anti-inflammatory drug (Deupirafenidone) in patients with IPF.
This study is a randomized, double-blind, being conducted at centers globally to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in 240 treatment naïve adult patients with IPF ≥ 40 years in age. Patients will be randomized in a ratio of 1:1:1:1 to receive treatment of LYT-100, pirfenidone, or placebo to be taken daily for up to 183 days (26 week treatment period) with the primary outcome of Rate of decline in Forced Vital Capacity (FVC; in mL) over 26 weeks. Secondary endpoints, including spirometry, inflammatory biomarkers, and patient-reported outcomes will also be evaluated.
After completion of the double-blind period of the study, patients may participate in a long-term extension to evaluate tolerability and long-term safety. Patients receiving LYT-100 in the double-blind period will continue the dose throughout the long-term extension. Patients receiving pirfenidone or placebo in the double-blind period will be re-randomized in a 1:1 ratio to receive LYT-100 550mg or 825mg TID dose throughout the long-term extension.
Healthy
mCPET Healthy Adults Study
Sign Up Here
This study will develop a reference values in healthy participants for a new diagnostic test of exercise capacity (called mCPET).
PH
UCAPE/SEARCH Study
ClinicalTrials.gov Identifier NCT05568927
The project will validate a clinical decision tree designed to improve timely diagnosis and treatment of patients with pulmonary embolism.
The proposed project will validate a clinical decision tree to distinguish among the various discrete outcomes cost-effectively through a hierarchical series of tests with the acronym SEARCH (for symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging and hemodynamics). Each step of the algorithm sorts a subset of patients into a diagnostic category unequivocally in a cost-effective manner. The categories are mutually exclusive and collectively exhaustive, so that each case falls into one, and only one, category.
Covid
Long COVID Rehabilitation Research Program
Long Covid is a syndrome where symptoms related to your initial COVID-19 infection persist for more than 3 months. There are currently no proven treatments for Long Haul COVID syndrome. We are doing this study to look at the effects of a 10-week, gentle and progressive exercise rehabilitation program on Long COVID symptoms, including physical fitness, mental health, and immune system.
RECOVER VITAL Study
ClinicalTrials.gov Identifier NCT05595369
This is study evaluates the effect of 15 and 25 days of a drug (Paxlovid) compared to placebo in Long COVID patients with fatigue, brain fog, and autonomic function. Participants will be randomized to study interventions or placebo/controls based on the arms that are actively enrolling at the time of randomization. Study interventions may be added or removed according to adaptive design and/or emerging evidence. When there are multiple study interventions available, randomization will occur based on appropriateness of each intervention for the participant as determined by the study protocol.
